AVBP Latest Headlines

ArriVent: Buy Rating Reaffirmed as Price Target Cut to $20 on Pipeline Update, ARR-217 Seen as Key Value Driver

at www.tipranks.com (Wed, 7-Oct 5:55 AM)

Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)

at www.tipranks.com (Wed, 7-Oct 5:50 AM)

AVBP Shares React After FURVENT Misses Primary PFS Endpoint Despite Higher Confirmed Response Rate at 240 mg

Market Chameleon (Tue, 6-Oct 9:03 AM)

ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22

at www.tipranks.com (Tue, 6-Oct 3:55 PM)

Analyst Maintains Buy on ArriVent Despite Trial Setback, Trims Price Target to $15 Ahead of Key ADC Data

at www.tipranks.com (Tue, 6-Oct 11:35 AM)

ArriVent plunges as lead asset fails in late-stage cancer trial

at seekingalpha.com (Tue, 6-Oct 10:02 AM)

ArriVent’s FURVENT Phase 3 Trial Misses Primary Endpoint

at www.tipranks.com (Tue, 6-Oct 8:29 AM)